koto_feja/E+ via Getty Images
aTyr Pharma (NASDAQ:ATYR) is a very interesting biotech to look into, that's because it is in the process of developing efzofitimod for the treatment of patients with pulmonary sarcoidosis in the ongoing phase 3
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.
